Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

About this Publication
Title
Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Pubmed ID
35365600 (View this publication on the PubMed website)
Digital Object Identifier
Publication
Blood Cancer J. 2022 Apr 1; Volume 12 (Issue 4): Pages 51
Authors
Chang VC, Khan AA, Huang WY, Katki HA, Purdue MP, Landgren O, Hofmann JN
Affiliations
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. chidan.chang@nih.gov.
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Abstract
N/A
Related CDAS Studies
Related CDAS Projects